Levetiracetam
Product Images NDC 53808-0377

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 53808-0377). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula For Levetiracetam (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 01)

FDA Label Image

Figure 1 (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 02)

The text appears to be a graph showing the percentage of patients versus the level of medication for three different groups: placebo, levetiracetam, and leveliracetam. The text also provides the sample size for each group.*

FDA Label Image

Table 2 (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 03)

The text describes a clinical study involving the use of Levetiracetam as a treatment for partial seizures. The study had 111 participants who took 1000 mg/day or 2000 mg/day of Levetiracetam and another group of 106 participants who were given a placebo. The results show that the use of Levetiracetam reduced partial seizure frequency by 17.1% and 21.4% respectively, which was statistically significant compared to the placebo group.*

FDA Label Image

Figure 2 (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 04)

This appears to be a statistical report of a clinical trial testing the efficacy of two different doses of Levetiracetam compared to a placebo. The percentage values represent the proportion of patients who experienced some benefit from the medication. The trial was conducted with 111 participants in the placebo group and N=106 and N=105 in the two Levetiracetam dose groups. There are some statistically significant differences between the medication groups and placebo, but without additional information, the nature of these differences is not clear.*

FDA Label Image

Table 3 (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 05)

The text describes a study of the drug Levetiracetam with 104 participants taking 3000mg per day and 180 participants taking a placebo. The study showed that Levetiracetam resulted in a 23.0% reduction in partial seizure frequency compared to the placebo group. This difference was statistically significant.*

FDA Label Image

Figure 3 (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 06)

This data table represents the percentage of patients who experienced a particular effect due to taking Levetiracetam 3000 mg/day compared to those who took Placebo (N-104). The values are statistically significant versus placebo. However, without further information on what the effects are, it is difficult to provide additional context.*

FDA Label Image

Table 4 (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 07)

The text describes the results of a study involving the medication Levetiracetam and its efficacy in reducing partial seizure frequency compared to a placebo. The study included 101 participants and resulted in a 26.8% reduction in partial seizure frequency, which was found to be statistically significant compared to the placebo.*

FDA Label Image

Figure 4 (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 08)

FDA Label Image

Table 5 (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 09)

This is a table showing the percentage of adverse events associated with the drug Levetiracetam compared to a placebo, categorized by body system. Some notable adverse events include asthenia, headache, infection, somnolence, dizziness, and diplopia.*

FDA Label Image

Table 6 (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 10)

This appears to be a list of adverse events experienced by patients who took Levetiracetam. It includes physical and neurological symptoms such as accidental injury, somnolence, and dizziness, as well as digestive issues like vomiting and diarrhea. Other symptoms mentioned include rhinitis, skin discoloration, and albuminuria.*

FDA Label Image

Table 7 (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 11)

This is a table that shows the percentage of patients who experienced certain side effects while taking either Levetiracetam or a placebo. Levetiracetam is associated with a higher incidence of convulsions, dizziness, rash and somnolence (sleepiness) compared to the placebo. Asthenia (weakness/fatigue) is more common among those on placebo.*

FDA Label Image

Table 8 (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 12)

This appears to be a table comparing the incidence of adverse reactions between subjects treated with Levetiracetam and those treated with placebo. The adverse effects reported include asthenia, hostility, and somnolence. The numbers in parentheses denote the percentage of subjects in the placebo group who experienced each reaction.*

FDA Label Image

Table 9 (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 13)

This is a dosage table for a particular medication, based on the patient's weight, for daily and BID (twice daily) dosing. The medication comes in 250mg and 500mg tablets, and the daily dose ranges from 500mg up to 3000mg depending on the patient's weight.*

FDA Label Image

Pediatric Dose Calculation (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 14)

This text appears to be a calculation formula for determining the daily dose of a medicine based on the patient's weight and a pre-defined dosage concentration of 100 mg/mL. The formula involves multiplying the daily dose in milligrams per kilogram by the patient's weight in kilograms to obtain the total daily dose in milliliters. This information may be useful for healthcare professionals and pharmacists who need to calculate accurate medication dosages for patients.*

FDA Label Image

Clcr Calculation (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 15)

This appears to be a formula for calculating estimated creatinine clearance, which is a measure of kidney function often used in medical settings. The formula involves taking the patient's age and weight, multiplying them together and then adjusting for gender (using 0.85 as a factor for female patients). Finally, the result is multiplied by the patient's serum creatinine level.*

FDA Label Image

Table 10 (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 16)

This is a dosage table for the medication with respect to creatinine clearance for patients with different levels of kidney function. The table provides recommended frequency and dosage for patients with normal, mild, moderate, and severe kidney impairments, as well as for patients with end-stage renal disease (ESRD) who use dialysis. A supplemental dosage is recommended post-dialysis for all ESRD patients.*

FDA Label Image

Glenmark Logo (432eafc0 Cf2c 4bed 9ede F63f9f4793b1 17)

FDA Label Image

Levetiracetam 500mg Label (Levetiracetam 500mg (glenmark))

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.